Clinical Trial Update: Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating vorolanib as monotherapy or in combination with toripalimab as adjuvant therapy for intermediate-high risk renal cell carcinoma, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Toripalimab (Toripalimab)
• Vorolanib (vorolanib)

Snippet

Sponsor: Dong Wen | Conditions: Renal Cell Carcinoma (RCC), Adjuvant | Phase 2 | Status: ACTIVE_NOT_RECRUITING